Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX).

Full DD Report for FOMX

You must become a subscriber to view this report.


Recent News from (NASDAQ: FOMX)

Foamix Pharmaceuticals misses by $0.23, misses on revenue
Foamix Pharmaceuticals (NASDAQ: FOMX ): Q3 GAAP EPS of -$0.38 misses by $0.23. More news on: Foamix Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:35
Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused...
Source: GlobeNewswire
Date: November, 07 2018 16:05
APC, NBL among premarket gainers
Daxor (NYSEMKT: DXR ) +13%  on contract from U.S. Army. More news on: Daxor Corp, Nano Dimension Ltd ADR, Foamix Pharmaceuticals, Stocks on the move, Top stock market news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 09:28
Foamix Pharma's FMX103 successful in late-stage rosacea studies; shares up 24% premarket
Foamix Pharmaceuticals (NASDAQ: FOMX ) is up  24%  premarket on light volume on the heels of its announcement of positive results from two Phase 3 clinical trials evaluating FMX103 for the treatment of patients with moderate-to-severe papulopustular rosacea , an acne-like skin c...
Source: SeekingAlpha
Date: November, 07 2018 06:44
Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (N...
Source: GlobeNewswire
Date: November, 07 2018 06:00
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in...
Source: GlobeNewswire
Date: October, 29 2018 08:00
Key events next week - healthcare
Noteworthy events during the week of October 14 - 20 for healthcare investors. More news on: Cannabics Pharmaceuticals Inc., Soligenix, Inc., Aeglea BioTherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 12 2018 08:52
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in ...
Source: GlobeNewswire
Date: October, 12 2018 08:00
Foamix up on positive late-stage data on acne candidate FMX101
Foamix Pharmaceuticals ( FOMX +0.3% ) is up at the open following its announcement of additional positive topline data from its third Phase 3 clinical trial evaluating topical acne candidate FMX101. More news on: Foamix Pharmaceuticals, Healthcare stocks news, Stocks on the move, R...
Source: SeekingAlpha
Date: October, 01 2018 09:33
Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
Statistically significant improvement demonstrated in reduction of non-inflammatory lesions Dermal tolerability scores consistent with previous Phase 3 studies Re-analysis including patients from discontinued investigator site consistent with primary ITT analysis for both co-prima...
Source: GlobeNewswire
Date: October, 01 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-085.745.836.065.61691,826
2018-05-175.305.355.435.2538,927
2017-02-029.9110.0110.189.85137,520
2017-02-0110.0810.0110.229.85141,168
2017-01-319.6510.0610.129.5897,305

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0728,17861,30545.9636Short
2018-12-0675,243182,19741.2976Short
2018-12-0446,876100,67446.5622Short
2018-12-0355,383107,37451.5795Short
2018-11-3044,382281,84715.7468Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FOMX.


About Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX)

Logo for Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FOMX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 16 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 12 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 11 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: FOMX)

      Daily Technical Chart for (NASDAQ: FOMX)


      Stay tuned for daily updates and more on (NASDAQ: FOMX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FOMX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FOMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FOMX and does not buy, sell, or trade any shares of FOMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/